October 27, 2015
GW Pharmaceuticals signs MOU to research Epudiolex with New South Wales (Australia)
GW Pharmaceuticals plc, has signed a Memorandum of Understanding (MOU) with the Government of New South Wales (NSW) in Australia to progress a research program for Epidiolex (cannabidiol or CBD) and cannabidivarin (CBDV) in children with severe, drug resistant childhood epilepsy.